Framingham, MA-based GTC Biotherapeutics (NASDAQ: [[ticker:GTCB]]) announced that its lead drug candidate, ATryn, has received orphan-drug status as a treatment for patients with a rare hereditary clotting disease. The drug—a protein produced it the milk of genetically engineered goats—was fast-tracked by the FDA back in September; GTC plans to complete its filings for approval of the drug in the first half of 2008.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
